UCB FIRST LOOK: Rystiggo obtains self-admin in EU
UCB announced that its FcRn inhibitor Rystiggo has received EU approval for two new administration methods for gMG patients. The drug can now be self-administered or administered by a caregiver using an infusion pump or manual push with a syringe. This approval is expected to enhance patient autonomy and satisfaction by reducing the need for frequent clinic visits, and comes in a heightening competitive environment where convenience could impact choice of treatment. UCB's Rystiggo remains the only approved FcRn inhibitor for both AChR+ and MusK+ gMG patients to date. We reiterate our € 214 TP and Accumulate rating.UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.